Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -64.99% is 18% above its 5-year average of -79.15%, near the high end of its 5-year range (-311.31%–-6.18%).
107.37% below its 12-month average of -31.34%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -17.63%.
RETURN ON ASSETS (ROA)
-64.99%
RETURN ON ASSETS (ROA) AVG TTM
-31.34%
RETURN ON ASSETS (ROA) AVG 3Y
-98.36%
RETURN ON ASSETS (ROA) AVG 5Y
-79.15%
RETURN ON ASSETS (ROA) AVG 10Y
-1118.08%
RETURN ON ASSETS (ROA) AVG 15Y
-139.98%
RETURN ON ASSETS (ROA) AVG 20Y
-61.37%
CURRENT VS TTM AVG
-107.37%
CURRENT VS 3Y AVG
+33.93%
CURRENT VS 5Y AVG
+17.89%
CURRENT VS 10Y AVG
+94.19%
CURRENT VS 15Y AVG
+53.57%
CURRENT VS 20Y AVG
-5.90%
SECTOR MEDIAN · HEALTHCARE
-30.70%
median of 713 covered companies
CURRENT VS SECTOR MEDIAN
-111.69%
vs the sector median at left
IM Cannabis Corp.
Market Cap
$1.14M
Return on Assets (ROA)
-64.99%
TTM Avg
-31.34%
3Y Avg
-98.36%
5Y Avg
-79.15%
Market Cap
$1.12M
Return on Assets (ROA)
-247.39%
TTM Avg
-97.35%
3Y Avg
-1378.80%
5Y Avg
-1078.71%
Market Cap
$1.16M
Return on Assets (ROA)
-147.60%
TTM Avg
-223.87%
3Y Avg
-1843.76%
5Y Avg
-4349.14%
Market Cap
$1.10M
Return on Assets (ROA)
-8.84%
TTM Avg
-4.56%
3Y Avg
8.88%
5Y Avg
8.88%
Market Cap
$1.07M
Return on Assets (ROA)
-44.32%
TTM Avg
-57.72%
3Y Avg
-286.30%
5Y Avg
-215.47%
Market Cap
$1.03M
Return on Assets (ROA)
-81.60%
TTM Avg
-1375.39%
3Y Avg
-681.84%
5Y Avg
-547.21%
Market Cap
$1.37M
Return on Assets (ROA)
-96.27%
TTM Avg
-335.81%
3Y Avg
-263.87%
5Y Avg
-193.48%
Market Cap
$1.39M
Return on Assets (ROA)
-72.52%
TTM Avg
-80.61%
3Y Avg
-249.55%
5Y Avg
-240.26%
Market Cap
$1.39M
Return on Assets (ROA)
-196.18%
TTM Avg
-334.48%
3Y Avg
-197.38%
5Y Avg
-169.68%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IM Cannabis Corp. (IMCC) | $1.14M | -64.99% | -31.34% | -98.36% | -79.15% |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.12M | -247.39% | -97.35% | -1378.80% | -1078.71% |
| Propanc Biopharma, Inc. (PPCB)vs › | $1.16M | -147.60% | -223.87% | -1843.76% | -4349.14% |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.10M | -8.84% | -4.56% | 8.88% | 8.88% |
| Clearmind Medicine Inc. (CMND)vs › | $1.07M | -44.32% | -57.72% | -286.30% | -215.47% |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.03M | -81.60% | -1375.39% | -681.84% | -547.21% |
| Genprex, Inc. (GNPX)vs › | $1.37M | -96.27% | -335.81% | -263.87% | -193.48% |
| NewcelX Ltd. (NCEL)vs › | $1.39M | -72.52% | -80.61% | -249.55% | -240.26% |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.39M | -196.18% | -334.48% | -197.38% | -169.68% |
| NEXGEL, Inc. (NXGL)vs › | $1.40M | -23.39% | -29.27% | -34.02% | -43.63% |
ROA
-65.0%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -35.67% |
| 2024-12-31 | -27.01% |
| 2023-12-31 | -19.46% |
| 2022-12-31 | -311.31% |
| 2021-12-31 | -6.18% |
| 2020-12-31 | -75.29% |
| 2019-12-31 | -23.60% |
| 2019-04-30 | 4548.28% |
| 2018-04-30 | 5884.28% |
| 2017-04-30 | -5706.52% |
| 2016-04-30 | -16526.45% |
| 2015-04-30 | -234.07% |
| 2014-04-30 | -794.79% |
| 2013-04-30 | -5831.04% |
| 2012-04-30 | -5.35% |
| 2011-04-30 | -7.08% |
| 2010-04-30 | -14.29% |
| 2009-04-30 | -22.06% |
| 2008-04-30 | -26.74% |
| 2007-04-30 | -36.49% |
| 2006-04-30 | -75.93% |
| 2005-04-30 | -0.45% |
| 2004-04-30 | -75.52% |
| 2003-04-30 | 0.00% |
| 2002-04-30 | 0.00% |
| 2001-04-30 | 0.00% |
| 2000-04-30 | 0.00% |
| 1999-04-30 | 0.00% |
| 1998-04-30 | 0.00% |
| 1997-04-30 | 0.00% |
